RHYTHM PHARMACEUTICALS, INC. Selling, General and Administrative Expense
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Selling, General and Administrative Expense of $67.45 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-04
- RHYTHM PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $67.45M, a 46.80% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $63.59M, a 62.69% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $57.48M, a 50.75% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $52.42M, a 48.19% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2025 was $194.94M, a 35.09% increase from fiscal 2024.
- RHYTHM PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2024 was $144.30M, a 22.78% increase from fiscal 2023.
- RHYTHM PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2023 was $117.53M, a 27.71% increase from fiscal 2022.
- RHYTHM PHARMACEUTICALS, INC. selling, general and administrative expense for fiscal 2022 was $92.03M, a 34.38% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $67.45M 10-Q · filed 2026-08-04 | $131.04M 10-Q · filed 2026-08-04 | $188.52M derived: sum of 3 quarters · filed 2026-08-04 | $240.94M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $63.59M 10-Q · filed 2026-05-05 | $121.07M derived: sum of 2 quarters · filed 2026-05-05 | $173.50M derived: sum of 3 quarters · filed 2026-05-05 | $219.44M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $57.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $109.91M derived: sum of 2 quarters · filed 2026-02-26 | $155.85M derived: sum of 3 quarters · filed 2026-08-04 | $194.94M 10-K · filed 2026-02-26 |
| 2025-09-30 | $52.42M 10-Q · filed 2025-11-04 | $98.37M derived: sum of 2 quarters · filed 2026-08-04 | $137.46M 10-Q · filed 2025-11-04 | $175.59M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $45.95M 10-Q · filed 2026-08-04 | $85.03M 10-Q · filed 2026-08-04 | $123.16M derived: sum of 3 quarters · filed 2026-08-04 | $158.54M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $39.09M 10-Q · filed 2026-05-05 | $77.22M derived: sum of 2 quarters · filed 2026-05-05 | $112.59M derived: sum of 3 quarters · filed 2026-05-05 | $149.01M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $38.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $73.51M derived: sum of 2 quarters · filed 2026-02-26 | $109.92M derived: sum of 3 quarters · filed 2026-02-26 | $144.30M 10-K · filed 2026-02-26 |
| 2024-09-30 | $35.38M 10-Q · filed 2025-11-04 | $71.79M derived: sum of 2 quarters · filed 2025-11-04 | $106.17M 10-Q · filed 2025-11-04 | $138.55M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $36.41M 10-Q · filed 2025-08-05 | $70.80M 10-Q · filed 2025-08-05 | $103.17M derived: sum of 3 quarters · filed 2026-02-26 | $133.65M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $34.38M 10-Q · filed 2025-05-07 | $66.76M derived: sum of 2 quarters · filed 2026-02-26 | $97.23M derived: sum of 3 quarters · filed 2026-02-26 | $127.28M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $32.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $62.85M derived: sum of 2 quarters · filed 2026-02-26 | $92.89M derived: sum of 3 quarters · filed 2026-02-26 | $117.53M 10-K · filed 2026-02-26 |
| 2023-09-30 | $30.48M 10-Q · filed 2024-11-06 | $60.52M derived: sum of 2 quarters · filed 2024-11-06 | $85.16M 10-Q · filed 2024-11-06 | $111.47M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $30.05M 10-Q · filed 2024-08-06 | $54.67M 10-Q · filed 2024-08-06 | $81.00M derived: sum of 3 quarters · filed 2025-02-28 | $102.94M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $24.63M 10-Q · filed 2024-05-07 | $50.95M derived: sum of 2 quarters · filed 2025-02-28 | $72.89M derived: sum of 3 quarters · filed 2025-02-28 | $95.22M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $26.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $48.26M derived: sum of 2 quarters · filed 2025-02-28 | $70.58M derived: sum of 3 quarters · filed 2025-02-28 | $92.03M 10-K · filed 2025-02-28 |
| 2022-09-30 | $21.94M 10-Q · filed 2023-11-08 | $44.27M derived: sum of 2 quarters · filed 2023-11-08 | $65.72M 10-Q · filed 2023-11-08 | $86.71M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $22.33M 10-Q · filed 2023-08-01 | $43.78M 10-Q · filed 2023-08-01 | $64.77M derived: sum of 3 quarters · filed 2024-02-29 | $82.28M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $21.45M 10-Q · filed 2023-05-02 | $42.45M derived: sum of 2 quarters · filed 2024-02-29 | $59.95M derived: sum of 3 quarters · filed 2024-02-29 | $75.42M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $21.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $38.50M derived: sum of 2 quarters · filed 2024-02-29 | $53.97M derived: sum of 3 quarters · filed 2024-02-29 | $68.49M 10-K · filed 2024-02-29 |
| 2021-09-30 | $17.51M 10-Q · filed 2022-11-08 | $32.97M derived: sum of 2 quarters · filed 2022-11-08 | $47.49M 10-Q · filed 2022-11-08 | $60.61M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $15.46M 10-Q · filed 2022-08-03 | $29.98M 10-Q · filed 2022-08-03 | $43.10M derived: sum of 3 quarters · filed 2023-03-01 | $54.39M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $14.52M 10-Q · filed 2022-05-03 | $27.64M derived: sum of 2 quarters · filed 2023-03-01 | $38.93M derived: sum of 3 quarters · filed 2023-03-01 | $47.85M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $13.12M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $24.41M derived: sum of 2 quarters · filed 2023-03-01 | $33.33M derived: sum of 3 quarters · filed 2023-03-01 | $46.13M 10-K · filed 2023-03-01 |
| 2020-09-30 | $11.29M 10-Q · filed 2021-11-02 | $20.21M derived: sum of 2 quarters · filed 2021-11-02 | $33.01M 10-Q · filed 2021-11-02 | $42.42M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $8.92M 10-Q · filed 2021-08-03 | $21.72M 10-Q · filed 2021-08-03 | $31.13M derived: sum of 3 quarters · filed 2022-03-01 | $41.67M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $12.80M 10-Q · filed 2021-05-03 | $22.21M derived: sum of 2 quarters · filed 2022-03-01 | $32.75M derived: sum of 3 quarters · filed 2022-03-01 | $41.59M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $9.41M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $19.95M derived: sum of 2 quarters · filed 2022-03-01 | $28.79M derived: sum of 3 quarters · filed 2022-03-01 | $36.55M 10-K · filed 2022-03-01 |
| 2019-09-30 | $10.54M 10-Q · filed 2020-11-02 | $19.38M derived: sum of 2 quarters · filed 2020-11-02 | $27.14M 10-Q · filed 2020-11-02 | $35.52M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $8.84M 10-Q · filed 2020-08-03 | $16.60M 10-Q · filed 2020-08-03 | $24.99M derived: sum of 3 quarters · filed 2021-03-01 | $33.53M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $7.76M 10-Q · filed 2020-05-04 | $16.15M derived: sum of 2 quarters · filed 2021-03-01 | $24.69M derived: sum of 3 quarters · filed 2021-03-01 | $31.12M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $8.39M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $16.93M derived: sum of 2 quarters · filed 2021-03-01 | $23.36M derived: sum of 3 quarters · filed 2021-03-01 | $28.08M 10-K · filed 2021-03-01 |
| 2018-09-30 | $8.54M 10-Q · filed 2019-11-01 | $14.98M derived: sum of 2 quarters · filed 2019-11-01 | $19.69M 10-Q · filed 2019-11-01 | $24.02M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $6.44M 10-Q · filed 2019-07-29 | $11.15M 10-Q · filed 2019-07-29 | $15.48M derived: sum of 3 quarters · filed 2020-03-02 | $17.80M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $4.71M 10-Q · filed 2019-05-03 | $9.04M derived: sum of 2 quarters · filed 2020-03-02 | $11.36M derived: sum of 3 quarters · filed 2020-03-02 | $12.72M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $4.33M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $6.64M derived: sum of 2 quarters · filed 2020-03-02 | $8.00M derived: sum of 3 quarters · filed 2020-03-02 | $9.52M 10-K · filed 2020-03-02 |
| 2017-09-30 | $2.31M 10-Q · filed 2018-11-09 | $3.67M derived: sum of 2 quarters · filed 2018-11-09 | $5.19M 10-Q · filed 2018-11-09 | |
| 2017-06-30 | $1.36M 10-Q · filed 2018-08-08 | $2.87M 10-Q · filed 2018-08-08 | ||
| 2017-03-31 | $1.52M 10-Q · filed 2018-05-14 | |||
| 2016-12-31 | $6.31M 10-K · filed 2019-03-08 | |||
| 2015-12-31 | $3.42M 8-K · filed 2018-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |